Vitamin D Deficiency: Testing and Treatment in Primary Care
Clinical Practice Update — Who to Test, Interpreting Thresholds, and Supplementation in Adults
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Evidence-based vitamin D deficiency testing and supplementation in adults
- Target Audience
- Family physicians, general practitioners, nurse practitioners, pharmacists
- Setting
- Primary care and community practice
- Source Evidence
- •Endocrine Society Clinical Practice Guideline on Vitamin D (2024)
- •US Preventive Services Task Force Recommendation on Vitamin D Screening (2021)
- •Institute of Medicine Dietary Reference Intakes for Calcium and Vitamin D (2011)
- •VITAL Trial — Vitamin D and Cardiovascular/Cancer Outcomes (NEJM, 2019)
Key Clinical Takeaways
Managing vitamin D deficiency in primary care comes down to three practical judgements: deciding who actually warrants a blood test, reading the serum result against a sensible threshold, and matching a supplementation regimen to the patient in front of you. The points below distil current evidence into actionable rules for the clinic.
- 1Do not screen the general healthy population — test only patients with symptoms or established risk factors → Who to Test
- 2Order serum 25-hydroxyvitamin D — not the 1,25 form — when assessing patients with osteoporosis risk or bone symptoms → Reading Results
- 3Treat a level below 30 nmol/L (12 ng/mL) as clear deficiency requiring repletion → Reading Results
- 4Choose cholecalciferol (D3) over ergocalciferol (D2) for routine repletion in most adults → Supplementation
- 5A daily maintenance dose is safer and just as effective as large intermittent bolus dosing → Supplementation
- 6Routine vitamin D for cardiovascular or cancer prevention is not supported by trial evidence → Evidence in Context
- 7Recheck a serum level only after roughly 3 months of consistent supplementation → Monitoring
- 8Investigate for malabsorption or non-adherence when a level fails to rise despite treatment → Special Populations
Who Should Be Tested for Vitamin D Deficiency
The most important decision in vitamin D deficiency assessment is made before any blood is drawn: whether to test at all. Population-wide screening of asymptomatic adults generates large numbers of borderline results, drives unnecessary supplementation, and has not been shown to improve outcomes. Reserve testing for those whose history points toward genuine risk.
Do not screen asymptomatic, low-risk adults for vitamin D deficiency. The evidence does not show that routine screening of the general population changes clinical outcomes.
Against Moderate Evidence USPSTF 2021Evaluate for testing in adults with metabolic bone disease, prior fragility fracture, or a clinical concern around falls prevention, where a measured level will directly guide management.
Moderate Rec Moderate Evidence Endocrine Society 2024Consider testing patients with malabsorptive conditions, chronic kidney or liver disease, or those on medications that accelerate vitamin D metabolism, since these groups are predisposed to true deficiency.
Conditional Rec Low Evidence Endocrine Society 2024Counsel patients on the limited value of testing when they request a vitamin D level purely for vague fatigue without other features, and offer dietary and lifestyle advice instead.
Conditional Rec Low Evidence USPSTF 2021Interpreting Thresholds in Vitamin D Deficiency
Serum 25-hydroxyvitamin D is the correct test for assessing status, because it reflects total body stores and has a long half-life. The active 1,25 form fluctuates rapidly and tells you little about repletion. Where the major bodies diverge is on the cut-off that defines deficiency, so it helps to anchor decisions to a small set of practical thresholds rather than a single magic number.
A workable way to read results: below 30 nmol/L (12 ng/mL) signals deficiency where bone health is at risk and repletion is warranted. The 30 to 50 nmol/L (12 to 20 ng/mL) range is insufficiency, where some patients benefit from supplementation, especially with bone disease or a rising parathyroid hormone. Above 50 nmol/L (20 ng/mL) is generally adequate for the musculoskeletal needs of most adults.
Order serum 25-hydroxyvitamin D as the test of choice when investigating suspected vitamin D deficiency. Do not request the 1,25-dihydroxy assay unless there is a specific concern such as a granulomatous disorder or unexplained hypercalcaemia.
Strong Rec High Evidence Endocrine Society 2024Initiate repletion therapy when the serum level falls below 30 nmol/L (12 ng/mL), as this band is consistently linked with impaired bone mineralisation and a higher risk of osteomalacia.
Strong Rec Moderate Evidence IOM 2011Avoid routine use of a high target such as 75 nmol/L (30 ng/mL) as a universal goal for healthy adults. Chasing higher numbers rarely adds musculoskeletal benefit and encourages over-supplementation.
Conditional Rec Moderate Evidence IOM 2011Choosing a Supplementation Strategy
Once treatment is indicated, two questions follow: which form, and what schedule. For most adults the answer is cholecalciferol given daily, with a higher loading phase reserved for those who are clearly deficient and need stores corrected promptly. Large infrequent bolus doses have fallen out of favour after signals of harm, including a paradoxical increase in falls at very high intermittent doses.
Prescribe cholecalciferol (vitamin D3) in preference to ergocalciferol (D2) for routine repletion, as D3 raises and sustains serum levels more reliably in most patients.
Strong Rec Moderate Evidence Endocrine Society 2024Start a daily maintenance dose in the region of 800 to 2000 IU for adults with confirmed deficiency, and ensure adequate dietary calcium intake to support the bone benefit of repletion.
Strong Rec Moderate Evidence IOM 2011Consider a time-limited loading regimen totalling roughly 300,000 IU spread over 6 to 10 weeks for symptomatic, profoundly deficient patients, then step down to daily maintenance.
Moderate Rec Low Evidence Endocrine Society 2024Do not use very high single annual bolus doses, which have been associated with an increased rate of falls and fractures rather than protection.
Against Moderate Evidence Endocrine Society 2024Supplementation Options at a Glance
| Patient Situation | Preferred Form & Dose | Schedule | Practical Tips |
|---|---|---|---|
| Mild insufficiency, low risk | D3 800–1000 IU daily | Maintenance only | Often achievable through diet and sensible sun exposure alone. |
| Confirmed deficiency | D3 1000–2000 IU daily | Daily, long term | Take with a fat-containing meal to aid absorption. |
| Severe, symptomatic deficiency | D3 loading ~300,000 IU total | Split over 6–10 weeks, then maintenance | Always follow loading with a maintenance dose or levels will fall again. |
| Malabsorption | Higher D3 doses, individualised | Daily, guided by levels | Standard doses frequently fail; recheck and titrate upward. |
Clinical Decision Pathway
A practical, question-based route through a suspected case. Work through the questions in order rather than reaching for a test first.
Special Populations and Persistent Deficiency
Certain groups need a tailored approach, both in how they are dosed and in how a poor response is interpreted. When a level stubbornly refuses to climb, the cause is usually adherence or absorption rather than an inadequate prescription.
Evaluate for activated vitamin D analogues rather than plain cholecalciferol alone in advanced chronic kidney disease, where impaired hydroxylation limits the response to standard supplements.
Moderate Rec Low Evidence Endocrine Society 2024Reassess adherence before escalating the dose when a serum level fails to improve, since missed doses are the commonest reason for an apparently treatment-resistant deficiency.
Moderate Rec Low Evidence Endocrine Society 2024Refer for further investigation when persistent deficiency continues despite confirmed adherence, looking for underlying malabsorption such as coeliac disease or prior bariatric surgery.
Moderate Rec Low Evidence Endocrine Society 2024Before assuming the regimen is too weak, confirm the patient is actually taking it, that the product is genuine D3 rather than a low-dose multivitamin, that doses are taken with food, and that no malabsorptive condition is at play. Only then is dose escalation the right next step.
Monitoring and Follow-Up
Over-monitoring is as much a problem as under-monitoring. Levels change slowly, so frequent rechecking wastes resources and rarely changes management.
| Parameter | When to Check | What to Look For | Common Pitfalls |
|---|---|---|---|
| Serum 25(OH)D | ~3 months after starting | Movement into the adequate range | Rechecking at a few weeks is too soon to be meaningful. |
| Serum calcium | If high-dose or symptoms of hypercalcaemia | Rising calcium signalling over-treatment | Easy to overlook in patients on multiple supplements. |
| Parathyroid hormone | If secondary hyperparathyroidism suspected | Elevation suggesting under-treated deficiency | Not needed for routine, uncomplicated repletion. |
| Ongoing review | Annually once stable | Maintained level on stable maintenance dose | Stopping maintenance prematurely lets levels fall back. |
Monitor serum 25-hydroxyvitamin D no sooner than about 3 months after a change in regimen, allowing time for stores to equilibrate before judging the response.
Moderate Rec Low Evidence Endocrine Society 2024Do not recheck levels repeatedly in stable, well-supplemented patients, as this adds cost without altering treatment.
Against Low Evidence USPSTF 2021Evidence in Context
What the trials actually show, where the guideline bodies line up, and where they pull apart.
Why Population Prevention Has Disappointed
Large randomised trials, including the VITAL trial, found that supplementing unselected adults did not lower the rate of cardiovascular events or invasive cancer. The benefit of vitamin D appears concentrated in correcting genuine deficiency for bone health, not in dosing an already-replete population.
Where the Guideline Bodies Agree
There is broad consensus that screening healthy adults is unwarranted, that 25-hydroxyvitamin D is the right test, and that a level below 30 nmol/L represents deficiency warranting treatment. The disagreements are about the gradations above that floor, not the floor itself.
Where They Differ: How High Is High Enough
Some frameworks set the adequacy bar at 50 nmol/L for bone health, while others have historically favoured a higher target nearer 75 nmol/L. The practical upshot is that a patient labelled insufficient under one definition may be considered perfectly adequate under another.
The Case Against Bolus Dosing
Trials of very large annual doses reported more falls and fractures in treated participants, a counterintuitive finding that has pushed practice firmly toward daily or weekly regimens over single megadoses.
References
- 1.Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024;109(8):1907–1947. doi:10.1210/clinem/dgae290
- 2.US Preventive Services Task Force. Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(14):1436–1442. doi:10.1001/jama.2021.3069
- 3.Ross AC, Manson JE, Abrams SA, et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine. J Clin Endocrinol Metab. 2011;96(1):53–58. doi:10.1210/jc.2010-2704
- 4.Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019;380(1):33–44. doi:10.1056/NEJMoa1809944
How to Read the Evidence Tags
Every recommendation carries two tags for recommendation strength and evidence quality — Medaptly’s own simplified interpretations, not reproduced from any single guideline body.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | The benefit is less certain — individualise. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |